12:00 AM
 | 
Aug 01, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TG1050: Phase I/Ib ongoing

Transgene said a safety review committee recommended continuation of a double-blind, placebo-controlled, international Phase I/Ib trial evaluating single injections and 3 once-weekly injections of TG1050 with standard antiviral therapy. The...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >